Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03424603 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 7, 2018
Last Update Posted : December 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| B-cell Lymphoma Non Hodgkin Lymphoma Multiple Myeloma Follicular Lymphoma Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma Indolent Lymphoma B Cells--Tumors | Drug: STRO-001 | Phase 1 |
This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who are refractory to, or intolerant of, all established therapy known to provide clinical benefit for their condition (i.e., trial subjects must not be candidates for any regimens known to provide clinical benefit). The study will consist of two parts: Part 1, dose escalation, and Part 2, dose expansion.
The study uses an accelerated dose titration design for dose escalation. Doses will be escalated using an N-of-1 per dosing cohort until the first instance of a treatment-related, clinically relevant Grade 2 non-hematologic toxicity or a Grade 3 hematologic toxicity of any type is observed during Cycle 1 (first 21 days). Following this a standard 3+3 trial design is used for all further escalation cohorts. Dose escalation is conducted independently for the two dose escalation tumor cohorts (MM and NHL). A recommended STRO-001 dose for expansion will be determined for MM and NHL.
The dose expansion (Part 2) portion of the study will begin when Part 1 is completed. Enrollment in dose expansion will include separate tumor cohorts of MM and NHL.
In both Part 1 and Part 2 of the study, STRO-001 will be dosed as an intravenous (IV) infusion on Day 1 of a 21-day cycle, until disease progression. Labs will be drawn on a weekly basis for Cycles 1-4, and every three weeks starting with Cycle 5. Weekly clinical evaluations will be conducted during the first 4 cycles; thereafter, clinical evaluations will be conducted on infusion days (Day 1 of each cycle). Samples for pharmacokinetics (PK) analysis will occur at specific times on Days 1, 2, and 8 of the first two cycles of treatment, Day 1 of the third cycle of treatment and at End of Treatment visit. Additional clinical evaluations and labs may occur at the discretion of the investigator.
Subjects who receive any dose of STRO-001 will be included in safety analyses. Disease evaluations will include peripheral blood analysis, bone marrow assessments and scans as appropriate. Disease status will be evaluated per MM-specific or NHL-specific criteria. Samples will be collected to assess the PK and immunogenicity of STRO-001. Biomarkers may be assessed from bone marrow, peripheral blood and/or tissue samples. Subjects will continue to receive study drug until disease progression, unacceptable toxicity, withdrawal of consent, or end of study (study completion).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 70 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies |
| Actual Study Start Date : | February 22, 2018 |
| Estimated Primary Completion Date : | January 2023 |
| Estimated Study Completion Date : | November 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: STRO-001
intravenous
|
Drug: STRO-001
intravenous antibody drug conjugate |
- Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001) [ Time Frame: 18 months ]Incidence of adverse events (AEs) observed across STRO-001 dose levels
- Part 1: Define the recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD) of STRO-001 [ Time Frame: 18 months ]Frequency of dose-limiting toxicity and exposure across STRO-001 dose levels
- Part 2: Evaluate preliminary anti-tumor activity (multiple myeloma patients) [ Time Frame: 24 months ]Objective response rates per International Myeloma Working Group (IMWG) criteria for response assessment
- Part 2: Evaluate preliminary anti-tumor activity (NHL patients) [ Time Frame: 24 months ]Objective response rates per the Lugano classification for response assessment
- Part 1: Characterize the pharmacokinetics (PK) of STRO-001 by measuring the maximum plasma concentration (Cmax) [ Time Frame: 18 months ]Measurement of maximum plasma concentration after the administration of STRO-001
- Part 1: Characterize the PK of STRO-001 by measuring the half-life (t1/2) of STRO-001 [ Time Frame: 18 months ]Measurement of terminal half-life of STRO-001 after the administration of STRO-001
- Part 1: Characterize the PK of STRO-001 measuring the total area under the concentration versus time curve from zero to infinity (AUCinf) [ Time Frame: 18 months ]Measurement of AUC to infinity (AUCinf)
- Part 1: Characterize the PK of STRO-001 by measuring the clearance (CL) [ Time Frame: 18 months ]Measurement of total body clearance
- Part 1: Characterize the PK of STRO-001 by measuring the the steady state volume of distribution (Vss) [ Time Frame: 18 months ]Measurement of steady state volume of distribution
- Part 1: Assess the immunogenic potential of STRO-001 [ Time Frame: 18 months ]Evaluation and quantitation of circulating anti-drug antibodies (ADAs) over time
- Part 2: Further evaluate the incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001) [ Time Frame: 24 months ]Number of patients with abnormal laboratory values and/or adverse events related to STRO-001 treatment
- Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of duration of response (DOR) in patients treated with STRO-001 [ Time Frame: 24 months ]Each cohort will be analyzed independently
- Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of progression-free survival (PFS) in patients treated with STRO-001 [ Time Frame: 24 months ]Each cohort will be analyzed independently
- Part 2: Characterize the PK of STRO-001 by measuring the maximum plasma concentration (Cmax) [ Time Frame: 24 months ]Measurement of maximum plasma concentration after the administration of STRO-001
- Part 2: Characterize the PK of STRO-001 by measuring the half-life (t1/2) of STRO-001 [ Time Frame: 24 months ]Measurement of terminal half-life of STRO-001 after the administration of STRO-001
- Part 2: Characterize the PK of STRO-001 by measuring the area under the plasma concentration versus time curve (AUC) [ Time Frame: 24 months ]Measurement of AUC to infinity (AUC inf)
- Part 2: Characterize the PK of STRO-001 by measuring the clearance (CL) [ Time Frame: 24 months ]Measurement of total body clearance
- Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (multiple myeloma patients) [ Time Frame: 18 months ]Objective response rates per IMWG criteria for response assessment
- Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (NHL) [ Time Frame: 18 months ]Objective response rates per the Lugano classification for response assessment (NHL patients)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Confirmation of diagnosis
- Relapsed or relapsed/refractory disease
- Age ≥ 18 years
- ECOG performance status (0-2)
- Life expectancy > 3 months
- Adequate bone marrow and renal functions
- QTcF <500 msec
- Ability to comply with treatment, PK and test schedules
- NHL only- at least one measurable lesion
Key Exclusion Criteria:
- Active plasma cell leukemia and/or leukemic manifestations of lymphoma
- Known amyloidosis (MM patients)
- Chronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects)
- T-cell malignancy
- Sensory or motor neuropathy ≥ grade 2
- Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
- Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Subjects may be using topical or inhaled corticosteroids.
- Clinically significant cardiac disease
- Significant concurrent, uncontrolled medical condition
- History or clinical signs of meningeal or active CNS involvement
- Known severe chronic obstructive pulmonary disease or asthma
- History of significant cerebrovascular disease
- Known Human Immunodeficiency Virus seropositivity
- Positive serology for hepatitis B defined by a positive test for HBsAg
- Concurrent participation in another therapeutic treatment trial
- High screening liver function tests
- Prior treatment with CD74 targeting therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03424603
Show 22 study locations
| Study Director: | Arturo Molina, MD | Sutro Biopharma |
| Responsible Party: | Sutro Biopharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT03424603 |
| Other Study ID Numbers: |
STRO-001-BCM1 |
| First Posted: | February 7, 2018 Key Record Dates |
| Last Update Posted: | December 14, 2022 |
| Last Verified: | December 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Lymphoma Multiple Myeloma Lymphoma, B-Cell Lymphoma, Mantle-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders |
Immune System Diseases Neoplasms, Plasma Cell Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoma, Non-Hodgkin |